Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Unnatural Products has developed an AI-driven platform that rapidly designs and optimizes orally bioavailable macrocyclic peptides targeting previously undruggable intracellular proteins. The company has demonstrated the ability to generate potent, selective compounds with improved cell permeability and oral bioavailability. Its technology has attracted partnerships with major biopharma companies like BridgeBio Pharma, which has licensed candidates for rare disease and oncology indications. No clinical results have been published yet; programs are in preclinical or earlier stages.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Unnatural 20 Studios.